Skip to main content
Clinical Trials/NCT03794401
NCT03794401UnknownNot Applicable

Alternations of Intestinal Microbiota and Health Impact in Chronic Kidney Disease (AIM-HI CKD): A Cohort Study

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation1 site in 1 country750 target enrollmentStarted: April 1, 2019Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
750
Locations
1
Primary Endpoint
renal outcome

Study Overview

Brief Summary

This study is aimed to evaluate the impact of dietary pattern, gut microbiota and their interactions on clinical outcomes among patient with CKD stage 3-5.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
20 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients with CKD stage 3-5 defined as eGFR <60 ml/min/1.73 m2 calculated with the use of the four-variable Modification of Diet in Renal Disease formula who have not yet on dialysis therapy.

Exclusion Criteria

  • Patients with active cancer
  • Patients with liver cirrhosis
  • Patients have taken antibiotics within three months before screening for inclusion.
  • Patients with a cardiac pacemaker or metallic implants,
  • Patients are amputees
  • Pregnant women
  • Patients with inherited renal diseases

Outcomes

Primary Outcomes

renal outcome

Time Frame: 3-year follow-up

a composite of ≥40% decrease in eGFR and ESRD needing chronic dialysis or preemptive kidney transplantation

cardiovascular outcome

Time Frame: 3-year follow-up

a composite of major adverse CV events, defined as CV death, myocardial infarction, or ischemic stroke

Secondary Outcomes

  • all-cause mortality(3-year follow-up)
  • neurological outcome(3-year follow-up)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Szu-Chun Hung

Attending physician

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Study Sites (1)

Loading locations...

Similar Trials

Alternations of Intestinal Microbiota and... | Clinical Trial